

IN THE CLAIMS:

1-14. (Canceled)

¹/~~15~~. (Previously amended) A chemical composition used to stimulate weight loss in a patient, consisting essentially of:

acarbose; and

a sustained release matrix, wherein said acarbose and sustained release matrix are combined to form a mixture.

²/~~16~~. (Original) The composition of claim ¹/~~15~~, wherein said acarbose is about 20% to about 40% by weight of said composition.

³/~~17~~. (Original) The composition of claim ¹/~~15~~, wherein said acarbose is present in an amount of about 25mg to about 300mg.

⁴/~~18~~. (Previously Amended) The composition of claim ¹/~~15~~, further consisting essentially of a filler.

⁵/~~19~~. (Previously Amended) The composition of claim ⁴/~~18~~, further consisting essentially of a glidant.

⁶/~~20~~. (Previously Amended) The composition of claim ⁵/~~19~~, further consisting essentially of a lubricant.

⁹/~~21~~. (Original) The composition of claim ⁵/~~19~~, wherein said glidant is selected from the group consisting of colloidal silica and precipitated silica.

⁷/~~22~~. (Original) The composition of claim ⁶/~~20~~, wherein said lubricant is selected from the group consisting of sodium lauryl sulfate, sodium stearyl fumarate, and metal stearates.

⁸/~~23~~. (Original) The composition of claim ⁶/~~20~~, wherein said lubricant is selected from the group consisting of magnesium stearate, zinc stearate, calcium stearate, and mixtures thereof.

¹⁰/₂₄. (Original) The composition of claim ¹/~~15~~, wherein said sustained release matrix is hydroxypropylmethylcellulose (HPMC).

¹¹/₂₅. (Original) The composition of claim ¹/~~15~~, wherein said composition is covered with a coating.

¹²/₂₆. (Original) The composition of claim ¹¹/~~25~~, wherein said coating is a cellulose ether-based coating.

¹³/₂₇. (Original) The composition of claim ¹¹/~~25~~, wherein said coating is a cellulose ether-based coating in combination with ethyl cellulose.

28-42. (Canceled)

¹⁴/₄₃. (Currently Amended) A method of treating a patient to stimulate weight loss comprising administering an sustained release acarbose formulation to the patient, wherein such formulation does not include a lipase inhibitor.